In analyses restricted to people without DM, for every 1000 participants treated for one year, allocation to an SGLT-2 inhibitor was estimated to prevent 33 HF hospitalizations or cardiovascular deaths in people with HFrEF, and prevent 15 such outcomes in corresponding analyses for HFpEF (Supplemental Table 3). The gene discussed is SLC5A2; the disease is diabetes mellitus.